Jeffrey Dayno
-
Plymouth Meeting Pharmaceutical Company Eyes $1B Milestone
Harmony Biosciences says its flagship narcolepsy drug is on track to hit a major milestone, writes John George for The…
-
Plymouth Meeting’s Harmony Biosciences Pivots After FDA Rejects Wakix for Sleep Disorder
Plymouth Meeting’s Harmony Biosciences’ stock fell 10% on Wednesday after the FDA rejected the expansion of its insomnia drug, Wakix,…
-
Plymouth Meeting’s Harmony Biosciences Eyes $3B in Sales with New Treatments on the Way
Since launching in 2017, Plymouth Meeting’s Harmony Biosciences has grown from a small drug developer into a billion-dollar company, writes…
-
Plymouth Meeting-based Harmony Biosciences Acquires Epygenix Therapeutics, Adds Potential Epilepsy Treatment to Pipeline
Plymouth Meeting-based Harmony Biosciences acquired Epygenix Therapeutics of Paramus, New Jersey, last month, which added a potential treatment for epilepsy…
-
Plymouth Meeting-based Harmony Biosciences Enters Exclusive Licensing Deal for Potential New Narcolepsy Therapy
Harmony Biosciences, a Plymouth Meeting-based pharmaceutical company, has entered into an exclusive licensing deal for the rights to develop and…
-
Plymouth Meeting’s Harmony Biosciences Holdings Acquires Zynerba Pharmaceuticals
Harmony Biosciences Holdings in Plymouth Meeting has agreed to buy Zynerba Pharmaceuticals for up to $200 million, writes John George…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
